345 related articles for article (PubMed ID: 28982896)
1. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
D'Andrea D; Moschini M; Soria F; Gust KM; Briganti A; Karakiewicz PI; Rouprêt M; Shariat SF
Anticancer Res; 2017 Oct; 37(10):5747-5753. PubMed ID: 28982896
[TBL] [Abstract][Full Text] [Related]
2. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
3. The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Gershman B; Moreira DM; Tollefson MK; Frank I; Cheville JC; Thapa P; Tarrell RF; Thompson RH; Boorjian SA
Urol Oncol; 2016 Jan; 34(1):4.e1-9. PubMed ID: 26329815
[TBL] [Abstract][Full Text] [Related]
4. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.
Engel O; Soave A; Peine S; Kluth LA; Schmid M; Shariat SF; Dahlem R; Fisch M; Rink M
World J Urol; 2015 Nov; 33(11):1769-76. PubMed ID: 25782867
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
Niegisch G; Nini A; Michalski R; Henn A; Mally D; Albers P; Rabenalt R
Urol Int; 2018; 101(2):224-231. PubMed ID: 30045033
[TBL] [Abstract][Full Text] [Related]
6. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
[TBL] [Abstract][Full Text] [Related]
8. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients.
Kluth LA; Rieken M; Xylinas E; Kent M; Rink M; Rouprêt M; Sharifi N; Jamzadeh A; Kassouf W; Kaushik D; Boorjian SA; Roghmann F; Noldus J; Masson-Lecomte A; Vordos D; Ikeda M; Matsumoto K; Hagiwara M; Kikuchi E; Fradet Y; Izawa J; Rendon R; Fairey A; Lotan Y; Bachmann A; Zerbib M; Fisch M; Scherr DS; Vickers A; Shariat SF
Eur Urol; 2014 Nov; 66(5):913-9. PubMed ID: 24331151
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
10. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery.
Nuhn P; Bastian PJ; Novara G; Svatek RS; Karakiewicz PI; Skinner E; Fradet Y; Izawa JI; Kassouf W; Montorsi F; Müller SC; Fritsche HM; Sonpavde G; Tilki D; Isbarn H; Ficarra V; Dinney CP; Shariat SF
Urol Int; 2011; 87(1):42-8. PubMed ID: 21659717
[TBL] [Abstract][Full Text] [Related]
11. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
12. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy.
Simone G; Papalia R; Ferriero M; Guaglianone S; Castelli E; Collura D; Muto G; Gallucci M
Int J Urol; 2013 Apr; 20(4):390-7. PubMed ID: 22970939
[TBL] [Abstract][Full Text] [Related]
14. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Kluth LA; Xylinas E; Rieken M; El Ghouayel M; Sun M; Karakiewicz PI; Lotan Y; Chun FK; Boorjian SA; Lee RK; Briganti A; Rouprêt M; Fisch M; Scherr DS; Shariat SF
BJU Int; 2014 Mar; 113(3):393-8. PubMed ID: 24053618
[TBL] [Abstract][Full Text] [Related]
15. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
Vetterlein MW; Gild P; Kluth LA; Seisen T; Gierth M; Fritsche HM; Burger M; Protzel C; Hakenberg OW; von Landenberg N; Roghmann F; Noldus J; Nuhn P; Pycha A; Rink M; Chun FK; May M; Fisch M; Aziz A;
BJU Int; 2018 Jan; 121(1):101-110. PubMed ID: 28905486
[TBL] [Abstract][Full Text] [Related]
16. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.
Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA
World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
[TBL] [Abstract][Full Text] [Related]
18. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
[TBL] [Abstract][Full Text] [Related]
19. Do blood groups have effect on prognosis of patients undergoing radical cystectomy?
Süer E; Özcan C; Gökçe I; Gülpınar Ö; Göğüş C; Türkölmez K; Baltacı S; Bedük Y
Int Urol Nephrol; 2014 Aug; 46(8):1521-6. PubMed ID: 24677002
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
